TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER

被引：0
|
作者：
Heng, Sharon [1 ]
Pokharel, Khageshwor [1 ]
Gilbar, Peter [1 ]
Tannock, Margot [1 ]
机构：
[1] Toowoomba Base Hosp, Dept Med Oncol, Toowoomba, Qld, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
321
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [31] Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
    Aye, T. T.
    Mon, S.
    Khine, M.
    Sein, N.
    Thant, N. M.
    Win, A. K.
    Aung, E. P. P.
    Hnin, P. T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] TRASTUZUMAB EMTANSINE FOR HER2 POSITIVE BREAST CANCER PATIENTS: AN UPDATED SYSTEMATIC REVIEW
    Valle, P. M.
    Mosegui, G. B.
    Vianna, C. M.
    Araujo, R. L.
    Felicissimo, T.
    Lima, I. J.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A816
  • [33] Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options
    Bae, Sangmee
    Hurvitz, Sara
    CURRENT CANCER THERAPY REVIEWS, 2015, 11 (04) : 269 - 291
  • [34] Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Laura Díaz-Gil
    Fara Brasó-Maristany
    Claudriana Locatelli
    Ariana Centa
    Balász Győrffy
    Alberto Ocaña
    Aleix Prat
    Atanasio Pandiella
    Journal of Experimental & Clinical Cancer Research, 40
  • [35] Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer
    Nilufer Bulut
    Hakan Harputluoglu
    Omer Dizdar
    Kadri Altundag
    Journal of Neuro-Oncology, 2008, 86 : 241 - 241
  • [36] Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Diaz-Gil, Laura
    Braso-Maristany, Fara
    Locatelli, Claudriana
    Centa, Ariana
    Gyorffy, Balasz
    Ocana, Alberto
    Prat, Aleix
    Pandiella, Atanasio
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [37] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
    Calamac, M.
    Minic, I.
    Tomasevic, Z.
    Oblakovic-Babic, J.
    Serovic, K.
    Djurmez, O.
    Dimitrijevic, M.
    Bozovic-Spasojevic, I.
    BREAST, 2021, 56 : S82 - S83
  • [38] Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies
    Pinto, Ana Catarina
    Ades, Felipe
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    BREAST, 2013, 22 : S152 - S155
  • [39] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [40] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
12345